Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026
Basics
Sector
Healthcare
Industry
Healthcare Plans
Country
United States
Market cap
1.5B USD
Enterprise value
1.3B USD
Full-time employees
1,849
Overall health
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 1.14 vs a peer median of 0.63), less short-term liquidity (current ratio 1.70 vs a peer median of 2.59) and more debt relative to equity (1.22× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.14 vs peers 0.63), less liquidity (current ratio 1.70 vs peers 2.59) and more debt vs equity (1.22× vs peers 0.22×)
About average: profitability
Ranks #552 of 1,157 healthcare companies (top 48%)
Shareholders being diluted. Shares outstanding up 11% from December 2022 to July 2026.
Alignment Healthcare had 11% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Alignment Healthcare had 11% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Alignment Healthcare made a profit per share in its latest year after a loss the year before.
Cash flow well above reported profit. Free cash flow is 4.4× reported profit.
Free cash flow is 4.4× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $959M in 2020 to $3.9B in 2025.
Alignment Healthcare's fiscal-year revenue rose in each of the five years to 2025, from $959M to $3.9B.
StockQuotient Score
53/ 100▲ 1 since Oct 27 closeOct 5 52 → Nov 4 53 (+1)
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Oct 27, 2026 close: Score 59 → 62
Share price -8.2%+3
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Alignment Healthcare
Is Alignment Healthcare getting weaker?
Its latest SEC filing (Jul 30, 2026) showed no major changes. Its overall score is 53/100, up 1 since Oct 28, 2026.
How is Alignment Healthcare valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 62/100 against 1,393 healthcare peers.EBITDA yield 7.5% vs a peer median of 4.0% (stronger than 72% of peers).EBITDA yield 7.5% vs peers 4.0% (stronger than 72% of peers).
Is Alignment Healthcare growing?
Yes, faster than most of its peers. Growth scores 91/100 against 1,393 healthcare peers.3-year revenue growth 41.3% vs a peer median of 5.8% (stronger than 91% of peers).3-year revenue growth 41.3% vs peers 5.8% (stronger than 91% of peers).
How profitable is Alignment Healthcare?
About as profitable as its peers. Profitability scores 45/100 against 1,393 healthcare peers.Return on assets 3.2% vs a peer median of 1.7% (stronger than 62% of peers).Return on assets 3.2% vs peers 1.7% (stronger than 62% of peers).Operating margin 1.2% vs a peer median of 7.1% (weaker than 65% of peers).Operating margin 1.2% vs peers 7.1% (weaker than 65% of peers).
How risky is Alignment Healthcare?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 1.22× vs a peer median of 0.22× (weaker than 85% of peers).Debt / equity 1.22× vs peers 0.22× (weaker than 85% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
4.3B USD
4.6B USD
+7.5%
Net income (12 months)
19.8M USD
40.7M USD
+105.5%
Operating margin
0.8%
1.2%
+0.4 pts
Free cash flow (12 months)
226.1M USD
177.5M USD
−21.5%
Debt
323.6M USD
324.1M USD
+0.1%
Cash
705.6M USD
693.5M USD
−1.7%
Shares outstanding
206.7M
207.4M
+0.3%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Healthcare Plans companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
-15.2%
-9.0%
-7.0%
-3.8%
0.4%
▲ 4.1 pts
Net margin
-16.7%
-10.4%
-8.1%
-4.7%
-0.0%
▲ 4.7 pts
Return on assets (ROA)
-31.0%
-23.6%
-25.0%
-16.4%
-0.1%
▲ 16 pts
Return on equity (ROE)
-63.8%
-62.8%
-94.3%
-128.2%
-0.4%
▲ 128 pts
Debt to equity
0.49×
0.68×
1.03×
3.22×
1.80×
▼ 44%
Interest coverage
-10.21×
-7.03×
-6.02×
-4.31×
0.93×
▲ 122%
ALHC price history
Price history is added with the daily price update and will appear after the next one.